Randomized double blind placebo-controlled clinical trial comparison vaginal with sublingual misoprostol in preoperative ripening of the cervix before operative -diagnostic hysteroscopy in premenopausal women in Mirzakuchak-khan hospital at 2010-2011

Randomized double blind placebo-controlled clinical trail comparison vaginal with sublingual misoprostol in preoperative ripening of the cervix before operative -diagnostic hystroscopy in premenopausal women in mirzakuchak-khan hospital at 2010-2011

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012272576N3

Enrollment

100

Registered

2011-04-06

Start date

2010-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopy. Non inflammatory disorder of cervix uteri, unspecified

Interventions

Intervention 1: 100 patients were randomly assigned to the following treatment regiment . The vaginal group recieved 400micg of misoprostol one time six hours before hysteroscopy (placed into the post

Treatment - Drugs

100 patients were randomly assigned to the following treatment regiment . The vaginal group recieved 400micg of misoprostol one time six hours before hysteroscopy (placed into the posterior vaginal f

The sublingual group received 400micg of misoprstol sublingually one time six hours before hysteroscopy and at the same time received one tablet of vitB6 as placebo

Eligibility

Sex/Gender

Female

Age

14 Years to 50 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: woman who gave consent for operative-diagnostic hysteroscopy; and were of reproductive age (i.e.; were premenopausal) ; and not pregnant at the time of presentation." The exclusion criteria: contraindication to PGs (history of severe asthma; glaucoma; preexisting cardiac disease; hypertension, or renal failure); significant uterovaginal prolapsed precluding the administration of vaginal tablets; or history of cervical surgery or cervical incompetency; women who had sub mucosal fibroma larger than 2cm (because of partial dilatation of cervix).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Duration of cervical dilatation time in with 9 hegar could be inserted after prescription of sublingual or vaginal misoprostol. Timepoint: 6houres after prescription of sublingual or vaginal misoprostol. Method of measurement: The largest hegar that could be passed without resistance was starting time of dilatation.	—

Secondary

Measure	Time frame
Complications of hysteroscopy. Timepoint: 6hours after misoprostol prescription. Method of measurement: clinical.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Davari Tanha

Tehran University ofMedical Sciences

fatedavari@yahoo.com+98 21 8889 7761

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026